This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
-
Merck: La administración de Vioxx (F)
Simons, Robert L.; Kindred, NatalieCase HBS-111S07Knowledge and CommunicationStarting at €5.74
-
ATH Technologies (E)
Simons, Robert L.; Packard, JenniferCase HBS-117017-EStrategySupplements the (A) case. Designed as an in-class handout.Starting at €5.74
-
Merck: Managing Vioxx (E)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-109084-EStarting at €5.74
-
ATH Technologies (E) (Spanish version)
Simons, Robert L.; Packard, JenniferCase HBS-118S07StrategySupplements the (A) case. Designed as an in-class handout.Starting at €5.74
-
Merck: La administración de Vioxx (E)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S06Knowledge and CommunicationStarting at €5.74
-
X Prize CEO Peter Diamandis on jackpots for innovation
Diamandis, Peter F.; Morse, GardinerArticle HBS-F0811F-EThe CEO of the X Prize Foundation explains how offering cash jackpots for breakthrough innovations can help solve problems big and small in fields like space exploration, energy, and education.Starting at €8.20
-
X Prize CEO Peter Diamandis on jackpots for innovation (Spanish version)
Diamandis, Peter F.; Morse, GardinerArticle HBS-F0811FThe CEO of the X Prize Foundation explains how offering cash jackpots for breakthrough innovations can help solve problems big and small in fields like space exploration, energy, and education.Starting at €8.20
-
Let Me Take You Down (Spanish version)
Kersten, E. L.; Buchanan, Leigh; Morse, GardinerArticle HBS-F0403CLeadership and People ManagementE. Lawrence Kersten thinks corporate America could use a good dose of demotivation. Carrying products that promise to "unleash the power of mediocrity," Kersten's company, Despair Inc., has just the ticket.Starting at €8.20
-
Managing Vioxx (A) (Spanish version)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S02Strategy(B) evidence of life-threatening side effects, (C) decision options, (D) announcement to withdraw Vioxx, (E) reaction by patients, shareholders, media, and regulators, (F) Merck fights back, and (G) wrap-up. At the end of the case series, students may conclude that doing the right thing sometimes requires very hard choices.Starting at €8.20